239 related articles for article (PubMed ID: 21128112)
1. Mitochondrial amplification selectively increases doxorubicin sensitivity in breast cancer cells with acquired antiestrogen resistance.
Skildum A; Dornfeld K; Wallace K
Breast Cancer Res Treat; 2011 Oct; 129(3):785-97. PubMed ID: 21128112
[TBL] [Abstract][Full Text] [Related]
2. Troglitazone Stimulates Cancer Cell Uptake of 18F-FDG by Suppressing Mitochondrial Respiration and Augments Sensitivity to Glucose Restriction.
Moon SH; Lee SJ; Jung KH; Quach CH; Park JW; Lee JH; Cho YS; Lee KH
J Nucl Med; 2016 Jan; 57(1):129-35. PubMed ID: 26449833
[TBL] [Abstract][Full Text] [Related]
3. Ligand for peroxisome proliferator-activated receptor gamma (troglitazone) has potent antitumor effect against human prostate cancer both in vitro and in vivo.
Kubota T; Koshizuka K; Williamson EA; Asou H; Said JW; Holden S; Miyoshi I; Koeffler HP
Cancer Res; 1998 Aug; 58(15):3344-52. PubMed ID: 9699665
[TBL] [Abstract][Full Text] [Related]
4. Stimulating basal mitochondrial respiration decreases doxorubicin apoptotic signaling in H9c2 cardiomyoblasts.
Deus CM; Zehowski C; Nordgren K; Wallace KB; Skildum A; Oliveira PJ
Toxicology; 2015 Aug; 334():1-11. PubMed ID: 25997894
[TBL] [Abstract][Full Text] [Related]
5. [Troglitazone sensitizes effect of epirubicin on breast cancer cells].
Sun JX; Meng ZX; Lv JH; Sun YJ
Ai Zheng; 2006 Aug; 25(8):960-6. PubMed ID: 16965675
[TBL] [Abstract][Full Text] [Related]
6. Mechanism of thiazolidinedione-dependent cell death in Jurkat T cells.
Soller M; Dröse S; Brandt U; Brüne B; von Knethen A
Mol Pharmacol; 2007 Jun; 71(6):1535-44. PubMed ID: 17325128
[TBL] [Abstract][Full Text] [Related]
7. Activation of peroxisome proliferator-activated receptor gamma in mammary epithelial cells upregulates the expression of tumor suppressor Cyld to mediate growth inhibition and anti-inflammatory effects.
Pseftogas A; Gonidas C; Mosialos G
Int J Biochem Cell Biol; 2017 Jan; 82():49-56. PubMed ID: 27865894
[TBL] [Abstract][Full Text] [Related]
8. PPARγ-inactive Δ2-troglitazone independently triggers ER stress and apoptosis in breast cancer cells.
Colin-Cassin C; Yao X; Cerella C; Chbicheb S; Kuntz S; Mazerbourg S; Boisbrun M; Chapleur Y; Diederich M; Flament S; Grillier-Vuissoz I
Mol Carcinog; 2015 May; 54(5):393-404. PubMed ID: 24293218
[TBL] [Abstract][Full Text] [Related]
9. Troglitazone suppresses telomerase activity independently of PPARgamma in estrogen-receptor negative breast cancer cells.
Rashid-Kolvear F; Taboski MA; Nguyen J; Wang DY; Harrington LA; Done SJ
BMC Cancer; 2010 Jul; 10():390. PubMed ID: 20650001
[TBL] [Abstract][Full Text] [Related]
10. Differential effects of peroxisome proliferator-activated receptor agonists on doxorubicin-resistant human myelogenous leukemia (K562/DOX) cells.
Yousefi B; Samadi N; Baradaran B; Rameshknia V; Shafiei-Irannejad V; Majidinia M; Targhaze N; Zarghami N
Cell Mol Biol (Noisy-le-grand); 2015 Dec; 61(8):118-22. PubMed ID: 26718439
[TBL] [Abstract][Full Text] [Related]
11. Synergistic interactions between heregulin and peroxisome proliferator-activated receptor-gamma (PPARgamma) agonist in breast cancer cells.
Park BH; Lee SB; Stolz DB; Lee YJ; Lee BC
J Biol Chem; 2011 Jun; 286(22):20087-99. PubMed ID: 21467033
[TBL] [Abstract][Full Text] [Related]
12. In vitro and in vivo therapeutic efficacy of the PPAR-γ agonist troglitazone in combination with cisplatin against malignant pleural mesothelioma cell growth.
Hamaguchi N; Hamada H; Miyoshi S; Irifune K; Ito R; Miyazaki T; Higaki J
Cancer Sci; 2010 Sep; 101(9):1955-64. PubMed ID: 20608936
[TBL] [Abstract][Full Text] [Related]
13. Treatment schedule and estrogen receptor-status influence acquisition of doxorubicin resistance in breast cancer cells.
Ponnusamy L; Mahalingaiah PKS; Singh KP
Eur J Pharm Sci; 2017 Jun; 104():424-433. PubMed ID: 28455002
[TBL] [Abstract][Full Text] [Related]
14. Induction of G1 phase arrest and apoptosis in MDA-MB-231 breast cancer cells by troglitazone, a synthetic peroxisome proliferator-activated receptor gamma (PPARgamma) ligand.
Yu HN; Lee YR; Noh EM; Lee KS; Kim JS; Song EK; Han MK; Lee YC; Kwon KB; Lee SJ; Youn HJ; Jung SH
Cell Biol Int; 2008 Aug; 32(8):906-12. PubMed ID: 18474441
[TBL] [Abstract][Full Text] [Related]
15. Troglitazone enhances tamoxifen-induced growth inhibitory activity of MCF-7 cells.
Yu HN; Noh EM; Lee YR; Roh SG; Song EK; Han MK; Lee YC; Shim IK; Lee SJ; Jung SH; Kim JS; Youn HJ
Biochem Biophys Res Commun; 2008 Dec; 377(1):242-7. PubMed ID: 18835379
[TBL] [Abstract][Full Text] [Related]
16. Peroxisome proliferator-activated receptor gamma ligand troglitazone induces cell cycle arrest and apoptosis of hepatocellular carcinoma cell lines.
Yoshizawa K; Cioca DP; Kawa S; Tanaka E; Kiyosawa K
Cancer; 2002 Nov; 95(10):2243-51. PubMed ID: 12412180
[TBL] [Abstract][Full Text] [Related]
17. Peroxisome proliferator-activated receptor gamma-independent ablation of cyclin D1 by thiazolidinediones and their derivatives in breast cancer cells.
Huang JW; Shiau CW; Yang YT; Kulp SK; Chen KF; Brueggemeier RW; Shapiro CL; Chen CS
Mol Pharmacol; 2005 Apr; 67(4):1342-8. PubMed ID: 15653552
[TBL] [Abstract][Full Text] [Related]
18. Troglitazone induces cytotoxicity in part by promoting the degradation of peroxisome proliferator-activated receptor γ co-activator-1α protein.
Liao X; Wang Y; Wong CW
Br J Pharmacol; 2010 Oct; 161(4):771-81. PubMed ID: 20860658
[TBL] [Abstract][Full Text] [Related]
19. Troglitazone is an estrogen-related receptor alpha and gamma inverse agonist.
Wang Y; Fang F; Wong CW
Biochem Pharmacol; 2010 Jul; 80(1):80-5. PubMed ID: 20298676
[TBL] [Abstract][Full Text] [Related]
20. Activation of peroxisome proliferator-activated receptor gamma by troglitazone inhibits cell growth through the increase of p27KiP1 in human. Pancreatic carcinoma cells.
Motomura W; Okumura T; Takahashi N; Obara T; Kohgo Y
Cancer Res; 2000 Oct; 60(19):5558-64. PubMed ID: 11034103
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
